Roche’s ALK-positive NSCLC drug granted FDA breakthrough designation

This second alecensa breakthrough therapy designation granted is based on phase 3 J-ALEX study.

Click on this link for more information.

Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submiss

Guideline on requirements for the production and control of immunological veterinary medicinal produ

What’s new in Pharmacovigilance? QPPV update (Issue 2, July 2017)